Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Restricted cash (USD, thousands)

Other noncurrent assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses and other current liabilities (USD, thousands)

Current portion of operating lease liabilities (USD, thousands)

Current portion of deferred revenue (USD, thousands)

Total current liabilities (USD, thousands)

Noncurrent operating lease liabilities (USD, thousands)

Total liabilities (USD, thousands)

Preferred stock, $ 0.001 par value (USD, thousands)

Common stock, $ 0.001 par value (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Accumulated other comprehensive income (loss) (USD, thousands)

Total stockholders' equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

5c967247f4f4ea70c89d83e18d8e5f513fc2b8f36aff7fc9cf13dc14be0e8d1f

Net loss [in thousands]

Stock-based compensation expense, excluding restructuring [in thousands]

Depreciation and amortization [in thousands]

Net amortization (accretion) on available-for-sale securities [in thousands]

Change in accrued interest on available-for-sale securities [in thousands]

Net cash used in operating activities [in thousands]

Purchase of property and equipment [in thousands]

Purchase of marketable securities [in thousands]

Maturities of marketable securities [in thousands]

Net cash provided by investing activities [in thousands]

Net cash provided by financing activities [in thousands]

Net increase (decrease) in cash and cash equivalents [in thousands]

Cash, cash equivalents and restricted cash at beginning of period [in thousands]

Cash, cash equivalents and restricted cash at end of period [in thousands]

Cash and cash equivalents at end of period (Supplemental) [in thousands]

Restricted cash at end of period (Supplemental) [in thousands]

0d474250515c4ca8bafa64f079cded1e3bc3ff6978112470977756bba5a26932

Revenue [USD, thousands]

Research and development expense [USD, thousands]

General and administrative expense [USD, thousands]

Impairment of long-lived assets and restructuring [USD, thousands]

Total operating expenses [USD, thousands]

Loss from operations [USD, thousands]

Interest income and other expense, net [USD, thousands]

Total other income (expense), net [USD, thousands]

Net loss [USD, thousands]

Net unrealized gain (loss) on available-for-sale securities [USD, thousands]

Comprehensive loss [USD, thousands]

830af9d44a94cf2b0af9d49637b9f4d5a3bed4755afef2d5f30ac2bcad836962

Number of discovery research programs in oncology with Genentech (programs)

925b0f20f5289e81f088972f26a0ef57f51e48007c8ddb7fae761f7c85f8fe59

Collaboration and License Agreement with Genentech

Total Revenue

84fe1fce04fd45162c97bd7ebbe5c0a4fb15ab9e96823cdd242c7e3d36fb9eac

Kronos Bio Inc (KRON)

Financials